Document Detail

Association between alopecia and response to chemotherapy in patients with Hodgkin lymphoma.
MedLine Citation:
PMID:  15905797     Owner:  NLM     Status:  MEDLINE    
Alopecia and bone marrow suppression are prominent effects of doxorubicin-containing chemotherapy. The aim of the study was to validate our preliminary clinical observation that the lack of alopecia in Hodgkin lymphoma patients may predict poor response to chemotherapy and low rate of bone marrow suppression. Sixty-six patients with Hodgkin lymphoma were reviewed. They were treated between 1991 and 2001 with at least 4 courses of doxorubicin-containing chemotherapy (MOPP/ABV or ABVD) in 2 university-affiliated hematology departments. Thirty-four patients exhibited complete or near complete alopecia, and 32 retained their hair or had only minimal hair loss. The 2 groups were compared by response to treatment and episodes of bone marrow suppression. Alopecia was associated with a high rate of remission (OR 8.48, 95% CI 2.77-25.95), episodes of neutropenia (OR 3.55, 95% CI 1.28-9.84), leukopenia (OR 1.83, 95% CI 0.68-4.92), delays in scheduled treatments (OR 1.61, 95% CI 0.607-4.30), or number of courses with dose reduction (OR 1.63, 95% CI 0.56-4.74). Significantly more patients with alopecia had at least 1 of these parameters (88% versus 62%, P=0.015; OR 4.50, 95% CI 1.27-15.94). In conclusion, in patients with Hodgkin lymphoma treated with doxorubicin-containing chemotherapy, the absence of alopecia may predict poor response to treatment along with fewer episodes of bone marrow suppression. The absence of alopecia in such patients should alert clinicians to the possibility of treatment failure.
Avishay Elis; Dorit Blickstein; Yosef Manor; Michael Lishner
Related Documents :
16649217 - Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of...
10485407 - Results after norwood procedure and subsequent cavopulmonary anastomoses for typical hy...
18983377 - The prognostic influence of prevertebral space involvement in nasopharyngeal carcinoma.
15359637 - Adjuvant radiotherapy in stage iv diffuse large cell lymphoma improves outcome.
24074777 - Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?
1142517 - Renal cell carcinoma: natural history and chemotherapeutic experience.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Therapeutic drug monitoring     Volume:  27     ISSN:  0163-4356     ISO Abbreviation:  Ther Drug Monit     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-05-20     Completed Date:  2005-09-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7909660     Medline TA:  Ther Drug Monit     Country:  United States    
Other Details:
Languages:  eng     Pagination:  287-9     Citation Subset:  IM    
Department of Medicine and Hematology, Meir Hospital, Kfar Saba, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alopecia / chemically induced*
Antibiotics, Antineoplastic / adverse effects*
Doxorubicin / adverse effects*
Hodgkin Disease / drug therapy*
Middle Aged
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 23214-92-8/Doxorubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Methylphenidate unintentional ingestion in preschool children.
Next Document:  Variation in health care provider definitions of moderate consumption of alcohol as related to recom...